Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
NEW YORK, Aug. 28, 2017 -- PHI Group, Inc., (www.phiglobal.com) (OTCQB:PHIL), a company focused on mergers and acquisitions and investments in natural resources, energy, agriculture, healthcare and special situations, announced today that it has formed PHIVITAE Corp., a Wyoming corporation, to serve as a holding subsidiary of the Company for pharmaceutical and healthcare-related business and signed a Letter of Intent (“LOI”) to acquire 80% of a 20-year old profitable European company that is engaged in pharmaceutical and medical device distribution.
According to the LOI, the Company will enter into a definitive purchase and sale agreement with the European target and will make cash payments for the purchase price, which will be finalized after completion of ongoing due diligence.
The Company intends to use the European target as a platform to distribute prized organic medicines developed by Tho Xuan Duong JSC, a company recognized by Guinness World Records with nearly four centuries of history in Vietnamese traditional medicine and herbs (www.thoxuanduong.com). It will also distribute FDA-cleared innovative medical devices using Low Level Laser Light Therapy technologies developed by American Laser Healthcare Corp, a Delaware corporation (Youtube: Mac Beam Inc), and other selective pharmaceutical products to the European markets.
The Company will announce further details after the signing of the definitive purchase and sale agreement and plans to close this transaction in six to eight weeks.
Henry Fahman, CEO of PHI Group, said, “We are very excited to acquire a majority interest in this European target which can serve as a platform to provide a variety of prized pharmaceutical products and medical devices to European countries and other geographical areas. The conclusion of this transaction will allow us to immediately consolidate its revenues and profits, which will potentially help our top and bottom lines as well as enhance our valuation in the market.”
About PHI Group
PHI Group (www.phiglobal.com) primarily focuses on mergers and acquisitions and invests in select industries and special situations that may substantially enhance shareholder value. PHI Group also provides M&A and consulting services through its wholly owned subsidiary, PHI Capital Holdings, Inc. (www.phicapitalholdings.com)
Safe Harbor
This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of such forward-looking statements pursuant to the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995.
Press Contact: Henry Fahman +1-702-475-5430 [email protected]
